The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Molecular characterization of human prostate carcinoma cell lines
Abstract
BACKGROUND: This study presents a comprehensive survey and characterization of available prostate carcinoma cell lines, most of which have been widely used but are incompletely characterized. METHODS: A total of 21 cell lines were investigated, including three “classical” (DU 145, LNCaP, and PC‐3) and 18 “non‐classical” lines (1013L, 22R v 1, ALVA‐55, ALVA‐101, ARCaP, CWR‐R1, DuCaP, DuPro‐1, LAPC‐4, MDA PCa 1, MDA PCa 2a, MDA PCa 2b, NCI‐H660, PC‐346C, PC‐93, PSK‐1, UM‐SCP‐1, and VCaP). Cytogenetics, DNA profiling, expression of basal, luminal, and neuroendocrine differentiation markers, and mutation analyses of the TP53 and androgen receptor (AR) genes were performed. RESULTS: Based on cytogenetics and DNA profiling analyses, out of the 18 “non‐classical” lines, six were confirmed to be unique, eight (in four pairs) were confirmed to be related in origin, and four lines were identified as cross‐contaminants. Of this latter group, PC‐93 was found to be a derivative of HeLa, whereas DuPro‐1, ALVA‐55, and ALVA‐101 were derivatives of PC‐3. The 17 genuine prostate cell lines expressed keratin 8 (K8) and K18. Nine showed AR expression, of which five harbored mutations in the AR gene. Prostate‐specific antigen and DD3 were exclusively detected in AR expressing cell lines. Seven lines expressed the basal cell marker K5, three of these lines showed co‐expression of AR. CONCLUSIONS: This study defines a collection of 17 genuine prostate carcinoma cell lines. This collection, although small, constitutes a variety of different types and stages of prostate cancer, while it also partly reflects the heterogeneous nature of this malignancy. Prostate 57: 205–225, 2003. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Establishment and characterization of a human prostatic carcinoma cell line (PC-3).
Kaighn, M. E., Ks, N., Ohnuki, Y., Lechner, J. F., & Jones, L. W. (1979) · PubMed · Cited by 2,123
LNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.
Bussemakers, M. J. G., van Bokhoven, A., Verhaegh, G. W. C. T., Smit, F. P., Karthaus, H. F. M., Schalken, J. A., Debruyne, F. M. J., Ru, N., & Isaacs, W. B. (1999) · PubMed · Cited by 1,051
Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., & Mulder, E. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80067-1 · Cited by 950
Isolation of a human prostate carcinoma cell line (DU 145)
Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H., & Paulson, D. F. (1978) · International Journal of Cancer · doi:10.1002/ijc.2910210305 · Cited by 926
(1986) · Lung Cancer · doi:10.1016/s0169-5002(86)80023-x · Cited by 900
Thalmann, G. N., Anezinis, P., Chang, S., Zhau, H. E., Kim, E. E., Hopwood, V. L., Pathak, S., von Eschenbach, A. C., & Chung, L. W. K. (1994) · PubMed · Cited by 727
p63 Is a Prostate Basal Cell Marker and Is Required for Prostate Development
Signoretti, S., Waltregny, D., Dilks, J., Isaac, B., Lin, D., Garraway, L., Yang, A., Montironi, R., McKeon, F., & Loda, M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64814-6 · Cited by 610
Cited by
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Beltran, H., Rickman, D. S., Park, K., Chae, S. S., Sboner, A., MacDonald, T. Y., Wang, Y., Sheikh, K. L., Terry, S., Tagawa, S. T., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0130 · Cited by 999
Patrawala, L., Calhoun, T., Schneider-Broussard, R., Li, H., Bhatia, B., Tang, S., Reilly, J. G., Chandra, D., Zhou, J., Claypool, K., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209327 · Cited by 968
Schweppe, R. E., Klopper, J. P., Korch, C., Pugazhenthi, U., Benezra, M., Knauf, J. A., Fagin, J. A., Marlow, L. A., Copland, J. A., Smallridge, R. C., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1102 · Cited by 563
Self-citationPC3 is a cell line characteristic of prostatic small cell carcinoma
Tai, S., Sun, Y., Squires, J. M., Zhang, H., Oh, W. K., Liang, C., & Huang, J. (2011) · The Prostate · doi:10.1002/pros.21383 · Cited by 438
Shi, X.-B., Xue, L., Yang, J., Ma, A.-H., Zhao, J., Xu, M., Tepper, C. G., Evans, C. P., Kung, H.-J., & deVere White, R. W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706641104 · Cited by 378
CELL LINES USED IN PROSTATE CANCER RESEARCH: A COMPENDIUM OF OLD AND NEW LINES—PART 1
SOBEL, R. E., & SADAR, M. D. (2005) · Journal of Urology · doi:10.1097/01.ju.0000141580.30910.57 · Cited by 364
Salami, J., Alabi, S., Willard, R. R., Vitale, N. J., Wang, J., Dong, H., Jin, M., McDonnell, D. P., Crew, A. P., Neklesa, T. K., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0105-8 · Cited by 349
Patrawala, L., Calhoun-Davis, T., Schneider-Broussard, R., & Tang, D. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0490 · Cited by 346
Härmä, V., Virtanen, J., Mäkelä, R., Happonen, A., Mpindi, J.-P., Knuuttila, M., Kohonen, P., Lötjönen, J., Kallioniemi, O., & Nees, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010431 · Cited by 344
Bisson, I., & Prowse, D. M. (2009) · Cell Research · doi:10.1038/cr.2009.43 · Cited by 308
Interleukin-8 Is a Molecular Determinant of Androgen Independence and Progression in Prostate Cancer
Araki, S., Omori, Y., Lyn, D., Singh, R. K., Meinbach, D. M., Sandman, Y., Lokeshwar, V. B., & Lokeshwar, B. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1162 · Cited by 275
Gan, Y., Shi, C., Inge, L., Hibner, M., Balducci, J., & Huang, Y. (2010) · Oncogene · doi:10.1038/onc.2010.240 · Cited by 266
Alimirah, F., Chen, J., Basrawala, Z., Xin, H., & Choubey, D. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.03.041 · Cited by 265
Recombinant Origin of the Retrovirus XMRV
Paprotka, T., Delviks-Frankenberry, K. A., Cingöz, O., Martinez, A., Kung, H.-J., Tepper, C. G., Hu, W.-S., Fivash, M. J., Coffin, J. M., & Pathak, V. K. (2011) · Science · doi:10.1126/science.1205292 · Cited by 240
Gao, H., Ouyang, X., Banach-Petrosky, W. A., Gerald, W. L., Shen, M. M., & Abate-Shen, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606836103 · Cited by 141
In vitro modeling of the prostate cancer microenvironment
Ellem, S. J., De-Juan-Pardo, E. M., & Risbridger, G. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.04.008 · Cited by 68
Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines
van Bokhoven, A., Caires, A., Maria, M. D., Schulte, A. P., Lucia, M. S., Nordeen, S. K., Miller, G. J., & Varella‐Garcia, M. (2003) · The Prostate · doi:10.1002/pros.10291 · Cited by 56
Self-citationPhosphorylation and activation of androgen receptor by Aurora-A.
Shu, S.-K., Liu, Q., Coppola, D., & Cheng, J. Q. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.121129 · Cited by 38
RetractedLu, T.-L., Han, C.-K., Chang, Y.-S., Lu, T.-J., Huang, H.-C., Bao, B.-Y., Wu, H.-Y., Huang, C.-H., Li, C.-Y., & Wu, T.-S. (2014) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x14500967 · Cited by 37
Lewis, H. D., Winter, A., Murphy, T. F., Tripathi, S., Pandey, V. N., & Barton, B. E. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0154 · Cited by 25
SLC4A4 promotes prostate cancer progression in vivo and in vitro via AKT-mediated signalling pathway
Liu, Z., Wang, Q., Zhai, G., Ke, S., Yu, X., & Guo, J. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02546-6 · Cited by 22
SILAC-based quantitative MS approach reveals Withaferin A regulated proteins in prostate cancer
Kumar, R., Nayak, D., & Somasekharan, S. P. (2021) · Journal of Proteomics · doi:10.1016/j.jprot.2021.104334 · Cited by 19
Metadata
- Authors
- van Bokhoven, A., Varella‐Garcia, M., Korch, C., Johannes, W. U., Smith, E. E., Miller, H. L., Nordeen, S. K., Miller, G. J., & Lucia, M. S.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2003-09-24
- Volume
- 57
- Issue
- 3
- Pages
- 205-225
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2023097049
- Cited by
- 633
- References
- 83
- FWCI
- 17.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.